New surgical robot gives doctors 'superhuman' precision
What looks like a video game is some of the most delicate surgery a doctor can perform.
'It's really a race against the clock and it's very tight and complex anatomy as well,' said Doctor Victor Chien, a plastic surgeon at Cedars Sinani specializing in facial and neck reconstructive surgery, especially after cancer.
He's demoing microsurgery to me – this is highly intricate surgery that typically involves blood vessels thinner than a human hair.
'This robot and the three-dimensional aspect of the visualization allows us to add efficiency add precision to these very difficult cases,' said Dr. Chien.
Dr. Chien recently performed the first FDA robot-assisted microsurgery for head and neck cancer.
The Symani Surgical System is remote-controlled. Doctors sit in a unique chair with hand controllers and use a 3D screen to guide the procedure.
The system helps in two ways. First, it magnifies the area doctors are operating on, making delicate procedures easier to perform. It also reduces natural tremors in the hand.
'It's going to open up a whole new avenue of treatments for patients for diseases we never even considered treating,' said Dr. Curtis L. Cetrulo, director of the Division of Plastic Surgery at Cedars-Sinai.
Cetrulo advocated for getting the system at the medical center and calls the first procedure a '100 percent success.'
The system is currently approved for head and neck microsurgery, but it could expand to procedures inside the brain, abdomen, and chest in the future.
'These tools allow us to use our mastery in a level of precision and a level of dedication that was not previously possible,' concluded Chien.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
The importance of donating blood to help others
WACO, Texas (FOX 44) – We at FOX 44 are teaming up with Carter BloodCare to host a Blood Drive this Friday, June 13th! With this, we would like to provide you with some additional information on the importance of donating. Carter BloodCare consultant Jessica Amara is here to share more. You can watch our interview in the video above. While no appointment is necessary for our Blood Drive, you can schedule an appointment online here. You can also scan the QR code below to sign up. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar
Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall issued on May 23 affects the 12-ounce aluminum cans of a 12-pack and 24-pack case of Dr Pepper Zero Sugar. 'Product labeled to be zero sugar contains full sugar product,' the FDA wrote about the drink. The recalled product contains the same amount of sugar found in regular Dr Pepper, which is 39 grams per can. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The cans were made by Pepsi Beverages Company in Jacksonville, Florida and distributed to only Florida, Georgia and South Carolina. On June 5, the FDA then classified the product as a class II recall. This level of recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. See the full recall here. Recall alert: These window air conditioners could cause mold exposure Recall alert: Bring these crackers back to the store due to undeclared allergen Recall alert: Throw away these 17 salads, salsas due to salmonella concern Read the original article on MassLive.
Yahoo
2 hours ago
- Yahoo
Parents are dismayed after FDA rejects experimental drug 4-year-old girl relies on
A family thought they had a life-changing drug for their 4-year-old daughter. Then the FDA rejected it. Channel 2's Michael Doudna heard from the girl's parents. For Hope Filchak, her daily routine includes a daily shot to help provide a normal life. However, soon the drug may go away. 'It's scary to think she might not have this in just a few months,' Caroline Filchak, Hope's mother, said. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] Hope was born with a rare mitochondrial disease that impacts fewer than 100 people in the world. The impacts are wide-ranging and a challenge to overcome. 'From early on, it was an uphill battle for Hope,' Caroline Filchak said. 'I think she's got 12 specialists that we see in three different states.' 'It affects her brain, her heart, her eyes and her ears, deafness, blindness, and then two heart defects,' Ben Filchak, Hope's father, said. There are no FDA-approved drugs for Hope's condition. So when heart troubles arose in 2024, the family was forced to turn to an experimental drug, elemipretide, and saw immediate improvement. 'Her energy increased, and her heart function has stabilized completely,' Ben Fiilchak said. However, last month, the FDA declined to give it approval. 'I would say that the FDA is trying to regulate two things, right. They're trying to make sure the products are safe, including drugs, but also that they are efficacious for people,' said Rossana Sanchez Russo, an Emory clinical geneticist. According to the parent company producing the drug, the FDA's rejection was in part because the FDA did not see an improvement in a six-minute walk test. 'We all know in the field that a six-minute walk test is not the be-all end-all outcome measure for mitochondrial diseases,' Amy Goldstein, a leading mitochondrial disease expert, said. She says the drug showed improvement in areas such as quality of life and cardiac health. 'I myself personally saved a baby in my cardiac ICU with Barre syndrome. He went home with no cardiac manifestations after arriving here in severe heart failure and needing a heart transplant,' Goldstein said. 'We were extremely disappointed that based on all of the data, they made the decision not to approve the drug.' Another hurdle rare disease drug testing faces is sample size. By its very nature, only a few people have these diseases, so getting a meaningful sample during clinical trials can be difficult. 'Sometimes we don't have enough burden of proof to be able to formally say that. That doesn't mean that it may not be working for a family or that it might not work for other conditions. It may mean that we just do not have all the data,' Sanchez Russo said. The FDA says the company behind the drug can reapply for approval, but it is unclear if it will be successful and how long the company can stay committed to producing a drug without the FDA giving an OK. Hope's family has a four-month supply of the drug left. However, they do not know how much longer access to the medicine will last. 'Hope is a special little girl, and she means so much to our family,' Caroline Filchak said. TRENDING STORIES: Raids uncover largest fentanyl pill operation in state history in Atlanta, Douglasville Hurricane season starts quietly in the Atlantic They were once best friends, then one killed the other. We take you inside this bizarre murder case [SIGN UP: WSB-TV Daily Headlines Newsletter]
